Catalyst

Slingshot members are tracking this event:

ContraVir (CTRV) Announces Positive Recommendation from Independent Data Safety Monitoring Board to Proceed to Phase 2a Testing Comparing CMX157 to Gilead's (GILD) Viread in Chronic Hepatitis B (HBV) Infection

Source Link:
http://www.nasdaq.com/press-release/cmx157-advances-headtohead-phase-2a-clinical-study-in-hepatitis-b-patients-with-favorable-20161017-00098

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
GILD
100%
CTRV
100%
SIGN ME UP
I want to vote! LOG ME IN
Now!
Slingshot Insights Explained
JOIN FOR FREE TODAY
Catalyst Date
Occurred on:
Oct 17, 2016
Related Projects Image

  • Don’t see a project related to the catalyst you care about?

Related Keywords Positive Recommendation, Independent Data Safety Monitoring Board, Phase 2a, Cmx157, Viread, Hbv, Chronic Hepatitis B Virus Infection
About Us
Media Center
Connect with Us
© 2024 Slingshot Insights. All rights reserved.